AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01928875 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine (Standard) Anesthesia Monitoring
Description: Standard of care monitoring
Study NCT00830856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole 800mg po qday
Study NCT00830856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose - Stavudine, lamivudine and Nevirapine
Description: Initiation within 72 hours of diagnosis of Cryptococcal meningitis.
Study NCT00830856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose - Stavudine, Lamivudine, Nevirapine
Description: Delayed initiation of ART defined as 10 weeks after initiation of high dose fluconazole therapy.
Study NCT04069806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: preoperative oral carbohydrate, preOp
Description: Patients in the experimental arm will receive oral carbohydrate preparation at 2 hours prior to planned caesarian section.
Study NCT01386372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Patients will receive full-dose oral tolvaptan therapy up to 1 month after randomization. During the initial 4 days of therapy, the dose of the study drug will be increased from 15 to 30 mg or from 30 to 60 mg according to a regimen designed for slow correction of serum sodium concentrations to 135 mEq/L or more Depending on the serum sodium concentration the dose will be increased or decreased. Patients will then be continued on their maintenance therapy with adjustments allowed to prevent hyponatremia and avoiding hypernatremia. As soon as normal serum sodium levels are achieved in at least two consecutive measurements the dose of the study drug will be progressively tapered according to an individually tailored weaning program
Study NCT01386372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Fluid restriction, normal or hypertonic saline, furosemide.
Study NCT00252382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNS-595 Injection
Description: Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.
Study NCT00776139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine Hydrochloride 10 mg tablet
Description: Bioequivalence Cetirizine Hydrochloride 10 mg tablet
Study NCT03028285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arginine sodium succinate
Description: Healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at 3 different combinations of dose and infusion rate under the close monitoring of vital signs and other safety parameters.
Study NCT03075683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Description: Eight sessions of internet-based CBT for insomnia comorbid with chronic pain, with active therapist support.
Study NCT03075683 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applied relaxation
Description: Eight sessions of internet-based applied relaxation for insomnia comorbid with chronic pain, with active therapist support.
Study NCT01154504 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: clinical treatment
Description: The clinical treatment will be optimized to gold standard international heart failure treatment
Study NCT01154504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrafiltration
Description: The ultrafiltration procedure will be done on Intensive Care Unit with automatic machine and HF 1400 filter. The fluid will be removed until a increased of 10% in hematocrit or clinical improvement.
Study NCT01154504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: isovolumetric hemofiltration
Description: The isovolumetric hemofiltration will be done in Intensive Care Unit for 8 hours, and will be permitted the diuretic use.The dose will be 35 ml/kg/hour and will e used automatic machine and MF1400 filter.Diuretic use will be maintained.
Study NCT00714207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NOT program
Description: Students in this arm of the study received the reformatted NOT intervention
Study NCT00714207 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NOT controls
Description: Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
Study NCT00714207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kicking Butts intervention
Description: Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
Study NCT05926219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatiguing Exercise
Description: Volunteers will perform knee extension exercise of the dominant limb while seated in a chair designed for exercise of the knee extensor muscle group. The chair will be equipped with a lever arm, aligned with the axis of rotation of the knee and fixed to the distal shank, 2 centimeters proximal to the ankle joint. The lever arm will be instrumented to provide resistance and measure velocity. The volunteers will perform 3-5 maximum voluntary contractions (MVC) to determine peak torque. Once established, volunteers will rest for 5 minutes before initiating the fatigue protocol, whereby they will perform repeated MVC of the dominant limb against resistance equal to or less than 50% of MVC until range of motion cannot be maintained. Because the goal of this exercise is to uniformly fatigue the quadriceps muscle group, this exercise will be performed continuously. It is expected to take between 1 and 3 minutes to achieve the desired level of fatigue.
Study NCT00582231 — intervention group
Intervention type: OTHER
Intervention: Questionnaires.
Description: Questionnaires.
Study NCT03249831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Intravenous
Study NCT03249831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit anti-thymocyte globulin
Description: Intravenous
Study NCT03249831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Initially IV. If patient tolerates, convert to oral.
Study NCT03249831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: IV or oral
Study NCT00921908 — intervention group
Intervention type: OTHER
Intervention: 2 mBq radioactive technetium diluted in 20 mL saline
Study NCT00714207 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KB controls
Description: Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
Study NCT02223728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Study NCT01245972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDL Treatment
Description: Pulsed-dye laser (PDL) treatment at one of two settings.
Study NCT04337528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic manipulation type thrust
Description: The osteopathic manipulation type thrust is applied to solve the sacroiliac joint dysfunction. This technique applies a high velocity and intensity push in a specified direction to correct the dysfunction produced by a not correct position or movement of one joint.
Study NCT04337528 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Osteopathic manipulation type thrust
Description: The osteopathic manipulation type thrust is applied to solve the sacroiliac joint dysfunction. This technique applies a high velocity and intensity push in a specified direction to correct the dysfunction produced by a not correct position or movement of one joint.
Study NCT04337528 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Osteopathic manipulation type muscle-energy
Description: The muscle-energy manipulation is applied to solve the sacroiliac joint dysfunction. This technique applies a movement with an intermittent resistance in a specified direction to correct the position or movement of one joint. The therapist applies the movement in the correct direction since he feels a limitation of movement. When he feels the limitation he requests to the participant pushing in the contrary direction without movement. After five or seven seconds the participant finishes the contraction and the therapist continues the correct movement since he feels once again the limitation, and he request to the participant contraction another five or seven seconds. The therapist request to the participant only three times, when he finish the three contraction and the therapy applies the last movement to correct direction the intervention finishes.
Study NCT04337528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulation type muscle-energy
Description: The muscle-energy manipulation is applied to solve the sacroiliac joint dysfunction. This technique applies a movement with an intermittent resistance in a specified direction to correct the position or movement of one joint. The therapist applies the movement in the correct direction since he feels a limitation of movement. When he feels the limitation he requests to the participant pushing in the contrary direction without movement. After five or seven seconds the participant finishes the contraction and the therapist continues the correct movement since he feels once again the limitation, and he request to the participant contraction another five or seven seconds. The therapist request to the participant only three times, when he finish the three contraction and the therapy applies the last movement to correct direction the intervention finishes.
Study NCT04337528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo technique
Description: The therapist simulates a false technique. The therapist applies movement in the sacroiliac joint without dysfunction, he applies movement since ninety degrees of pelvic flexion, and he wait sixty seconds. Whit this placebo technique the sacroiliac joint with the dysfunction is not altered.
Study NCT04337528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo technique
Description: The therapist simulates a false technique. The therapist applies movement in the sacroiliac joint without dysfunction, he applies movement since ninety degrees of pelvic flexion, and he wait sixty seconds. Whit this placebo technique the sacroiliac joint with the dysfunction is not altered.
Study NCT01628458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation (RFA)
Description: RFA with CELON bipolar probes. Settings: Power 30 watts, total energy 15 KJ.
Study NCT02870348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 MP
Description: Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as alpha1-antitrypsin.
Study NCT00578396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: grapes
Description: 1 pound of seedless red grapes
Study NCT00578396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: grapes
Description: 2/3 lb/day fresh red grapes
Study NCT00578396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: grapes
Description: 1/3 lb/day fresh red grapes
Study NCT05364658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvene IOL
Description: Indicated for Implantation in the human eye after removal of a cataractous crystalline lens
Study NCT03511924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intradialytic resistance training
Description: Progressive resistance training programme performed during haemodialysis, taking into account subject´s medical review summarizing: A. full medical history, B. clinical examination including cardiovascular assessment, C. detailed medication usage history, D. review of recent biochemistry and haematology records and results of lower extremity muscle strength assessments. Construction of intradialytic training programme followed recommendations published by the Exercise \& Sports Science Australia (Smart et al., 2013).
Study NCT02499640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion cold water
Description: immersion cold water at different temperatures and exposure times
Study NCT06054594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: After baseline testing, participants followed a progressive resistance training program 3 times a week for 4 months.
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Experimental therapy in randomizations R-HR and R-MR
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Experimental therapy in randomization R-eHR
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Daunorubicin
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myocet
Description: Part of intensification block Myocet-FLA for patients with very high relapse risk
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myocet
Description: Part of intensification block Myocet-FLA for patients with very high relapse risk
Study NCT00416663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of autologous ACPs
Description: Stem cells type:ACPs. At least 1.5 million of ACPs per one time of treatment
Study NCT04028765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Oral misoprostol 50 mcg every 4 hours for up to 6 doses or until cervical ripening is no longer indicated
Study NCT04028765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: IV Oxytocin 2 milliunits (mU)/min, increased by 2mU/min q15 minutes per hospital protocol
Study NCT04175912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04175912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT04175912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV
Study NCT03315910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: two counseling sessions
Study NCT03315910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day
Study NCT03315910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Lozenge
Description: 6 packs of NRT 2mg lozenge
Study NCT03315910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Framing
Description: health communication literature and quitting messages
Study NCT03315910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saliva sample
Description: saliva samples from those reporting abstinence and analyze samples
Study NCT00297895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Completion Lymphadenectomy
Description: complete lymph node dissection of lymph node basin with positive node
Study NCT00297895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring with nodal ultrasound
Description: serial ultrasound monitoring of SLND positive basin. If recurrence detected, subject has CLND.
Study NCT03249831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
Description: Infusion
Study NCT01404286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: After the adaptation sessions, volunteers underwent a session of resistance training at 60% of 1 RM organized as follows: 3 sets of 10 to 12 repetitions on each exercise machine with a 1 minute and 30 second interval between each set and an interval of 2 minutes between each exercise machine, giving a total duration of training between 50 and 60 minutes. The sequence of exercise machines used was alternated by body segment. The sessions were performed at the same time of day (morning) under controlled temperature conditions (24 ± 21C).
Study NCT02223728 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Education
Study NCT04056754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Subjects administered 4 tablets abiraterone acetate twice daily in 28-day cycle.
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Part of standard chemotherapy
Study NCT01654094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P6 Low Adherent Dressing
Description: Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
Study NCT01654094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
Study NCT03683446 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic rectal surgery
Description: Minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon.
Study NCT03683446 — intervention group
Intervention type: PROCEDURE
Intervention: Open rectal surgery
Description: Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
Study NCT05025189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Table Grape Powder
Description: Freeze Dried Whole Table Grape Powder
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Part of intensification block Myocet-FLA for patients with very high relapse risk
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Part of intensification block Myocet-FLA for patients with very high relapse risk
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Part of standard chemotherapy